Review: Receptor Targeted Nuclear Imaging of Breast Cancer
AbstractReceptor targeted nuclear imaging directed against molecular markers overexpressed on breast cancer (BC) cells offers a sensitive and specific method for BC imaging. Currently, a few targets such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), somatostatin receptor (SSTR), and the gastrin releasing peptide receptor (GRPR) are being investigated for this purpose. Expression of these targets is BC subtype dependent and information that can be gained from lesion visualization is dependent on the target; ER-targeting radiotracers, e.g., can be used to monitor response to anti-estrogen treatment. Here we give an overview of the studies currently under investigation for receptor targeted nuclear imaging of BC. Main findings of imaging studies are summarized and (potential) purposes of lesion visualization by targeting these molecular markers are discussed. Since BC is a very heterogeneous disease and molecular target expression can vary per subtype, but also during disease progression or under influence of treatment, radiotracers for selected imaging purposes should be chosen carefully. View Full-Text
Share & Cite This Article
Dalm, S.U.; Verzijlbergen, J.F.; De Jong, M. Review: Receptor Targeted Nuclear Imaging of Breast Cancer. Int. J. Mol. Sci. 2017, 18, 260.
Dalm SU, Verzijlbergen JF, De Jong M. Review: Receptor Targeted Nuclear Imaging of Breast Cancer. International Journal of Molecular Sciences. 2017; 18(2):260.Chicago/Turabian Style
Dalm, Simone U.; Verzijlbergen, John F.; De Jong, Marion. 2017. "Review: Receptor Targeted Nuclear Imaging of Breast Cancer." Int. J. Mol. Sci. 18, no. 2: 260.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.